Eliquis Sprinkle Patent Expiration

Eliquis Sprinkle is a drug owned by Bristol Myers Squibb Co. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 22, 2041. Details of Eliquis Sprinkle's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(1 year, 4 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11896586

(Pediatric)

Apixaban formulations
May, 2041

(15 years from now)

Active
US11896586 Apixaban formulations
Nov, 2040

(15 years from now)

Active
US6967208

(Pediatric)

Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
May, 2027

(1 year, 10 months from now)

Active


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Eliquis Sprinkle and ongoing litigations to help you estimate the early arrival of Eliquis Sprinkle generic.

Eliquis Sprinkle's Litigations

Eliquis Sprinkle been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 13, 2015, against patent number US6967208. The petitioner Coalition for Affordable Drugs IX, LLC, challenged the validity of this patent, with Bristol-Myers Squibb Company as the respondent. Click below to track the latest information on how companies are challenging Eliquis Sprinkle's patents.

Last updated on July 1, 2025
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6967208 August, 2015 Terminated-Denied
(22 Feb, 2016)
Bristol-Myers Squibb Company Coalition for Affordable Drugs IX, LLC


FDA has granted some exclusivities to Eliquis Sprinkle. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Eliquis Sprinkle, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Eliquis Sprinkle.

Exclusivity Information

Eliquis Sprinkle holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Eliquis Sprinkle's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 17, 2028
Pediatric Exclusivity(PED) Oct 17, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Eliquis Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eliquis Sprinkle's family patents as well as insights into ongoing legal events on those patents.

Eliquis Sprinkle's Family Patents

Eliquis Sprinkle has patent protection in a total of 38 countries. It's US patent count contributes only to 25.3% of its total global patent coverage. 27 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Eliquis Sprinkle.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Eliquis Sprinkle's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Eliquis Sprinkle Generic API suppliers:

Apixaban is the generic name for the brand Eliquis Sprinkle. 13 different companies have already filed for the generic of Eliquis Sprinkle, with Accord Hlthcare having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Eliquis Sprinkle's generic

Alternative Brands for Eliquis Sprinkle

There are several other brand drugs using the same active ingredient (Apixaban) as Eliquis Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Bristol Myers Squibb
Eliquis


Apart from brand drugs containing the same ingredient, some generics have also been filed for Apixaban, Eliquis Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Eliquis Sprinkle





About Eliquis Sprinkle

Eliquis Sprinkle is a drug owned by Bristol Myers Squibb Co. Eliquis Sprinkle uses Apixaban as an active ingredient. Eliquis Sprinkle was launched by Bristol in 2025.

Approval Date:

Eliquis Sprinkle was approved by FDA for market use on 17 April, 2025.

Active Ingredient:

Eliquis Sprinkle uses Apixaban as the active ingredient. Check out other Drugs and Companies using Apixaban ingredient

Dosage:

Eliquis Sprinkle is available in for suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.15MG FOR SUSPENSION Prescription ORAL